Travere Therapeutics, Inc. (TVTX): Cost of Revenue
$10.34M
Year ended 2025-12-31
$8.26M
Trailing 12 months to 2026-06-30
+32.7%
3-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.34M | +33.5% | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | $7.74M | -32.4% | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | $11.45M | +159.0% | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | $4.42M | +15.8% | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | $3.82M | n/c | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $6.13M | +17.0% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $5.23M | -5.3% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $5.53M | +53.3% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $3.60M | -20.8% | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | $4.55M | +108.4% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $2.19M | +282.7% | 2018-07-06, From 2015-01-01 |
| 2014-12-31 | $571.0K | n/a | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $0 | n/a | 2016-02-26, From 2013-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $10.34M | +33.5% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $132.42M | +2.1% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $20.96M | +440.5% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $190.52M | +29.5% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $336.35M | -3.6% |
| Organogenesis Holdings Inc. (ORGO) | 2024-12-31 | $115.74M | +8.7% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $39.54M | -21.8% |
| Insmed Inc (INSM) | 2025-12-31 | $122.94M | +43.4% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $400.94M | -18.9% |
Compare TVTX, NATR, BBIO, ZLAB side by side · Screen every company in Pharmaceutical Preparations ↗